On February 23, 2015, a response to the disclosure statement with respect to a plan of reorganization or liquidation was filed in the bankruptcy case of New England Compounding Pharmacy, Inc. and its affiliates.
The filing was assigned docket number 1166 and is described on the court’s official docket as follows:
Response To the Objection of Liberty Industries, Inc. To the Corrected Disclosure Statement and Lead MDL Counsel’s Notice to the Court Regarding the Potential for Limits on the Payment of Attorney’s Fees with certificate of service filed by Interested Party Lead Counsel for Plaintiffs’ Steering Committee Re: (Attachments: # (1) Exhibit A # (2) Exhibit B # (3) Exhibit C # (4) Exhibit D # (5) Exhibit E # (6) Exhibit F # (7) Exhibit G) (Sobol, Thomas)
New England Compounding Pharmacy, Inc. filed for bankruptcy protection, or had an involuntary bankruptcy petition filed against it, on December 21, 2012. The bankruptcy case is pending before the United States Bankruptcy Court for the District of Massachusetts. The case number for the lead bankruptcy case is 12-19882. The bankruptcy case is currently assigned to United States Bankruptcy Judge Henry Boroff. The law firm of Murtha Cullina LLP is acting as lead bankruptcy counsel to New England Compounding Pharmacy, Inc. in the bankruptcy case.